{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:13:11Z","timestamp":1791915191392,"version":"4.3.4"},"reference-count":99,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.atherosclerosis.2011.07.019","type":"journal-article","created":{"date-parts":[[2011,7,25]],"date-time":"2011-07-25T15:51:32Z","timestamp":1311609092000},"page":"15-21","source":"Crossref","is-referenced-by-count":110,"title":["Apolipoprotein A-V; a potent triglyceride reducer"],"prefix":"10.1016","volume":"219","author":[{"given":"Stefan K.","family":"Nilsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Heeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunilla","family":"Olivecrona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Merkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0005","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1126\/science.1064852","article-title":"An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing","volume":"294","author":"Pennacchio","year":"2001","journal-title":"Science (New York, N.Y)"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0010","doi-asserted-by":"crossref","first-page":"44512","DOI":"10.1074\/jbc.M106888200","article-title":"Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration","volume":"276","author":"van der Vliet","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0015","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1373\/clinchem.2004.040824","article-title":"The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins","volume":"51","author":"O\u2019Brien","year":"2005","journal-title":"Clin Chem"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0020","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1172\/JCI26712","article-title":"Give me A5 for lipoprotein hydrolysis","volume":"115","author":"Merkel","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0025","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1373\/clinchem.2005.061374","article-title":"Definitive N-terminal protein sequence and further characterization of the novel apolipoprotein A5 in human serum","volume":"52","author":"Alborn","year":"2006","journal-title":"Clin Chem"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0030","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cca.2006.07.014","article-title":"Association of human serum apolipoprotein A5 with lipid profiles affected by gender","volume":"376","author":"Zhao","year":"2007","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0035","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1194\/jlr.D500018-JLR200","article-title":"A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration","volume":"46","author":"Ishihara","year":"2005","journal-title":"J Lipid Res"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2011.07.019_bib0040","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00125-006-0261-0","article-title":"Plasma apolipoprotein A5 and triglycerides in type 2 diabetes","volume":"49","author":"Dallinga-Thie","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0045","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1194\/jlr.M500533-JLR200","article-title":"Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia","volume":"47","author":"Schaap","year":"2006","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0050","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1194\/jlr.M600233-JLR200","article-title":"Apolipoprotein A-V, triglycerides and risk of coronary artery disease: the prospective Epic-Norfolk Population Study","volume":"47","author":"Vaessen","year":"2006","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0055","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1007\/s00125-006-0387-0","article-title":"The apolipoprotein A-V genotype and plasma apolipoprotein A-V and triglyceride levels: prospective risk of type 2 diabetes. Results from the Northwick Park Heart Study II","volume":"49","author":"Talmud","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0060","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.atherosclerosis.2006.05.030","article-title":"Plasma apoAV levels are markedly elevated in severe hypertriglyceridemia and positively correlated with the APOA5 S19W polymorphism","volume":"193","author":"Henneman","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0065","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1161\/01.ATV.0000203519.25116.54","article-title":"Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics","volume":"26","author":"Chan","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0070","doi-asserted-by":"crossref","first-page":"21553","DOI":"10.1074\/jbc.M411412200","article-title":"Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase","volume":"280","author":"Merkel","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0075","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1194\/jlr.M700281-JLR200","article-title":"Effect of apolipoprotein A-V on plasma triglyceride, lipoprotein size, and composition in genetically engineered mice","volume":"49","author":"Nelbach","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0080","doi-asserted-by":"crossref","first-page":"27941","DOI":"10.1074\/jbc.M403240200","article-title":"ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis","volume":"279","author":"Schaap","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0085","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1194\/jlr.M800551-JLR200","article-title":"Plasma apolipoprotein AV levels in mice are positively associated with plasma triglyceride levels","volume":"50","author":"Vaessen","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0090","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00043798-199604000-00014","article-title":"Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies","volume":"3","author":"Hokanson","year":"1996","journal-title":"J Cardiovasc Risk"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0095","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1093\/hmg\/11.24.3031","article-title":"Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels","volume":"11","author":"Pennacchio","year":"2002","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0100","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1194\/jlr.M700011-JLR200","article-title":"APOA5 variants and metabolic syndrome in Caucasians","volume":"48","author":"Grallert","year":"2007","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0105","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.atherosclerosis.2005.06.043","article-title":"SNPs at the APOA5 gene account for the strong association with hypertriglyceridaemia at the APOA5\/A4\/C3\/A1 locus on chromosome 11q23 in the Northern Irish population","volume":"185","author":"Wright","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0110","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1194\/jlr.M400192-JLR200","article-title":"Influence of the APOA5 locus on plasma triglyceride, lipoprotein subclasses, and CVD risk in the Framingham Heart Study","volume":"45","author":"Lai","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0115","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/1471-2350-11-120","article-title":"Association of the apolipoprotein A5 gene \u22121131 T>C polymorphism with fasting blood lipids: a meta-analysis in 37859 subjects","volume":"11","author":"Zhao","year":"2010","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0120","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/ng.628","article-title":"Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia","volume":"42","author":"Johansen","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0125","doi-asserted-by":"crossref","DOI":"10.1007\/s10545-008-0863-4","article-title":"Apoprotein A-V: an important regulator of triglyceride metabolism","author":"Kluger","year":"2008","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0130","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1161\/ATVBAHA.109.188912","article-title":"Genetic association and interaction analysis of USF1 and APOA5 on lipid levels and atherosclerosis","volume":"30","author":"Laurila","year":"2010","journal-title":"Arterioscler Thromb Vascr Biol"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0135","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0140-6736(10)60545-4","article-title":"Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0140","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng.76","article-title":"Newly identified loci that influence lipid concentrations and risk of coronary artery disease","volume":"40","author":"Willer","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0145","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.atherosclerosis.2005.05.031","article-title":"Genetic variations of apolipoprotein A5 gene is associated with the risk of coronary artery disease among Chinese in Taiwan","volume":"185","author":"Hsu","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0150","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.trsl.2009.06.005","article-title":"Association between sequence variant of c.553 G>T in the apolipoprotein A5 gene and metabolic syndrome, insulin resistance, and carotid atherosclerosis","volume":"154","author":"Chien","year":"2009","journal-title":"Transl Res"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0155","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1515\/CCLM.2008.352","article-title":"Apolipoprotein A5 gene \u22121131T\/C polymorphism is associated with the risk of metabolic syndrome in ethnic Chinese in Taiwan","volume":"46","author":"Hsu","year":"2008","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0160","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1471-2350-9-84","article-title":"The APOA5 Trp19 allele is associated with metabolic syndrome via its association with plasma triglycerides","volume":"9","author":"Dallongeville","year":"2008","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0165","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00109-006-0147-0","article-title":"APOA5 gene variation modulates the effects of dietary fat intake on body mass index and obesity risk in the Framingham Heart Study","volume":"85","author":"Corella","year":"2007","journal-title":"J Mol Med (Berlin, Germany)"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0170","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1399-0004.2005.00463.x","article-title":"A polymorphism in the apolipoprotein A5 gene is associated with weight loss after short-term diet","volume":"68","author":"Aberle","year":"2005","journal-title":"Clin Genet"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0175","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00041433-200406000-00002","article-title":"The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism?","volume":"15","author":"van Dijk","year":"2004","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0180","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.metabol.2008.11.018","article-title":"Overexpression of apolipoprotein A5 in mice is not protective against body weight gain and aberrant glucose homeostasis","volume":"58","author":"Pamir","year":"2009","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0185","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCRESAHA.108.179861","article-title":"Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemia","volume":"103","author":"Mansouri","year":"2008","journal-title":"Circ Res"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0190","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2796.2011.02361.x","article-title":"Childhood-onset chylomicronaemia with reduced plasma lipoprotein lipase activity and mass: identification of a novel GPIHBP1 mutation","author":"Coca-Prieto","year":"2011","journal-title":"J Intern Med"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0195","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1194\/jlr.M002717","article-title":"Mutation of conserved cysteines in the Ly6 domain of GPIHBP1 in familial chylomicronemia","volume":"51","author":"Olivecrona","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0200","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1161\/ATVBAHA.109.186577","article-title":"Chylomicronemia with a mutant GPIHBP1 (Q115P) that cannot bind lipoprotein lipase","volume":"29","author":"Beigneux","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0205","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1476-511X-6-23","article-title":"Homozygous missense mutation (G56R) in glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPI-HBP1) in two siblings with fasting chylomicronemia (MIM 144650)","volume":"6","author":"Wang","year":"2007","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0210","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1038\/ng.2007.24","article-title":"Mutations in LMF1 cause combined lipase deficiency and severe hypertriglyceridemia","volume":"39","author":"Peterfy","year":"2007","journal-title":"Nat Genet"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0215","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cmet.2010.04.016","article-title":"GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries","volume":"12","author":"Davies","year":"2010","journal-title":"Cell Metab"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0220","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/01.ATV.0000153087.36428.dd","article-title":"Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia","volume":"25","author":"Priore Oliva","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0225","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1172\/JCI24471","article-title":"Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment","volume":"115","author":"Marcais","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0230","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1161\/ATVBAHA.108.172866","article-title":"Effects of six APOA5 variants, identified in patients with severe hypertriglyceridemia, on in vitro lipoprotein lipase activity and receptor binding","volume":"28","author":"Dorfmeister","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0235","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.atherosclerosis.2006.04.010","article-title":"A novel sequence variant in APOA5 gene found in patients with severe hypertriglyceridemia","volume":"188","author":"Priore Oliva","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0240","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.atherosclerosis.2009.03.046","article-title":"A novel APOA5 splicing mutation IVS2+1g>a in a Japanese chylomicronemia patient","volume":"207","author":"Okubo","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0245","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.atherosclerosis.2009.04.021","article-title":"Modulation of phenotypic expression of APOA5 Q97X and L242P mutations","volume":"207","author":"Charriere","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0250","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2796.2007.01889.x","article-title":"Estrogen induced hypertriglyceridemia in an apolipoprotein AV deficient patient","volume":"263","author":"Henneman","year":"2008","journal-title":"J Intern Med"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0255","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1086\/597099","article-title":"Association of single-nucleotide polymorphism 3 and c.553G>T of APOA5 with hypertriglyceridemia after treatment with highly active antiretroviral therapy containing protease inhibitors in hiv-infected individuals in Taiwan","volume":"48","author":"Chang","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0260","doi-asserted-by":"crossref","first-page":"17982","DOI":"10.1074\/jbc.M212191200","article-title":"Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators","volume":"278","author":"Vu-Dac","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0265","doi-asserted-by":"crossref","first-page":"25468","DOI":"10.1074\/jbc.M301302200","article-title":"The human apolipoprotein AV gene is regulated by peroxisome proliferator-activated receptor-alpha and contains a novel farnesoid X-activated receptor response element","volume":"278","author":"Prieur","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0270","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1161\/01.ATV.0000163841.85333.83","article-title":"Transcriptional regulation of apolipoprotein A5 gene expression by the nuclear receptor RORalpha","volume":"25","author":"Genoux","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0275","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1210\/me.2005-0048","volume":"19","author":"Prieur","year":"2005","journal-title":"Mol Endocrinol (Baltimore, MD)"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0280","doi-asserted-by":"crossref","first-page":"27533","DOI":"10.1074\/jbc.M503139200","article-title":"Thyroid hormone regulates the hypotriglyceridemic gene APOA5","volume":"280","author":"Prieur","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0285","doi-asserted-by":"crossref","first-page":"45462","DOI":"10.1074\/jbc.M404744200","article-title":"The liver X receptor ligand T0901317 down-regulates APOA5 gene expression through activation of SREBP-1c","volume":"279","author":"Jakel","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0290","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1128\/MCB.25.4.1537-1548.2005","article-title":"Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factor","volume":"25","author":"Nowak","year":"2005","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0295","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jmb.2008.04.057","article-title":"Glucose regulates the expression of the apolipoprotein A5 gene","volume":"380","author":"Nowak","year":"2008","journal-title":"J Mol Biol"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0300","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bbrc.2009.12.168","article-title":"Orphan nuclear receptor Nur77 participates in human apolipoprotein A5 gene expression","volume":"392","author":"Song","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0305","doi-asserted-by":"crossref","first-page":"9416","DOI":"10.1021\/bi034509t","article-title":"Structure-function studies of human apolipoprotein A-V: a regulator of plasma lipid homeostasis","volume":"42","author":"Beckstead","year":"2003","journal-title":"Biochemistry"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0310","doi-asserted-by":"crossref","first-page":"8768","DOI":"10.1021\/bi800515c","article-title":"The N-terminus of apolipoprotein A-V adopts a helix bundle molecular architecture","volume":"47","author":"Wong","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0315","doi-asserted-by":"crossref","first-page":"33369","DOI":"10.1074\/jbc.M109.040972","article-title":"Apolipoprotein A-V N-terminal domain lipid interaction properties in vitro explain the hypertriglyceridemic phenotype associated with natural truncation mutants","volume":"284","author":"Wong-Mauldin","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0320","doi-asserted-by":"crossref","first-page":"15484","DOI":"10.1074\/jbc.M611797200","article-title":"The C terminus of apolipoprotein A-V modulates lipid-binding activity","volume":"282","author":"Beckstead","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0325","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.chemphyslip.2006.04.004","article-title":"Identification of lipid binding and lipoprotein lipase activation domains of human apoAV","volume":"143","author":"Sun","year":"2006","journal-title":"Chem Phys Lipids"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0330","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.bbalip.2007.10.005","article-title":"Normal binding of lipoprotein lipase, chylomicrons, and apo-AV to GPIHBP1 containing a G56R amino acid substitution","volume":"1771","author":"Gin","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0335","doi-asserted-by":"crossref","first-page":"29554","DOI":"10.1074\/jbc.M802579200","article-title":"The acidic domain of GPIHBP1 is important for the binding of lipoprotein lipase and chylomicrons","volume":"283","author":"Gin","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0340","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1006\/bbrc.2000.2530","article-title":"Contribution of the carboxy-terminal domain of lipoprotein lipase to interaction with heparin and lipoproteins","volume":"271","author":"Lookene","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0345","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1021\/bi7000533","article-title":"Apolipoprotein A-V interaction with members of the low density lipoprotein receptor gene family","volume":"46","author":"Nilsson","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0350","doi-asserted-by":"crossref","first-page":"25383","DOI":"10.1074\/jbc.M501589200","article-title":"Apolipoprotein A-V-heparin interactions: implications for plasma lipoprotein metabolism","volume":"280","author":"Lookene","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0355","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1159\/000257484","article-title":"Apolipoprotein A-V modulates insulin secretion in pancreatic beta-cells through its interaction with midkine","volume":"24","author":"Helleboid-Chapman","year":"2009","journal-title":"Cell Physiol Biochem"},{"issue":"Suppl. 3","key":"10.1016\/j.atherosclerosis.2011.07.019_bib0360","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1046\/j.1365-2362.32.s3.3.x","article-title":"Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction","volume":"32","author":"Boden","year":"2002","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0365","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1161\/01.ATV.0000186189.26141.12","article-title":"Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants","volume":"25","author":"Grosskopf","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0370","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/01.mpa.0000163176.59920.b1","article-title":"Impact of apolipoprotein A5 polymorphisms on insulin sensitivity and beta-cell function","volume":"30","author":"Chiu","year":"2005","journal-title":"Pancreas"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0375","doi-asserted-by":"crossref","first-page":"34438","DOI":"10.1074\/jbc.M303784200","article-title":"Structure and interfacial properties of human apolipoprotein A-V","volume":"278","author":"Weinberg","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0380","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1194\/jlr.M800111-JLR200","article-title":"Intracellular lipid droplet targeting by apolipoprotein A-V requires the carboxyl-terminal segment","volume":"49","author":"Shu","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0385","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1194\/jlr.C700002-JLR200","article-title":"Apolipoprotein A-V association with intracellular lipid droplets","volume":"48","author":"Shu","year":"2007","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0390","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.cmet.2010.08.006","article-title":"Sort1, encoded by the cardiovascular risk locus 1p13.3, is a regulator of hepatic lipoprotein export","volume":"12","author":"Kjolby","year":"2010","journal-title":"Cell Metab"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0395","doi-asserted-by":"crossref","first-page":"25920","DOI":"10.1074\/jbc.M802721200","article-title":"Endocytosis of apolipoprotein A-V by members of the low density lipoprotein receptor and the VPS10p domain receptor families","volume":"283","author":"Nilsson","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0400","doi-asserted-by":"crossref","first-page":"28215","DOI":"10.1074\/jbc.M502144200","article-title":"Determination of the functionality of common APOA5 polymorphisms","volume":"280","author":"Talmud","year":"2005","journal-title":"J Biol Chem"},{"issue":"Suppl.","key":"10.1016\/j.atherosclerosis.2011.07.019_bib0405","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.1194\/jlr.R800050-JLR200","article-title":"The ins (cell) and outs (plasma) of apolipoprotein A-V","volume":"50","author":"Forte","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0410","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.bbrc.2004.05.003","article-title":"Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5","volume":"319","author":"Fruchart-Najib","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0415","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.bbalip.2010.02.004","article-title":"Apolipoprotein A-V associates with intrahepatic lipid droplets and influences triglyceride accumulation","volume":"1801","author":"Shu","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0420","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/hep.22473","article-title":"Altered hepatic triglyceride content after partial hepatectomy without impaired liver regeneration in multiple murine genetic models","volume":"48","author":"Newberry","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0425","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.atherosclerosis.2006.12.010","article-title":"Rare APOA5 mutations\u2014clinical consequences, metabolic and functional effects: an ENID review","volume":"194","author":"Talmud","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0430","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/MOL.0b013e3281527914","article-title":"GPIHBP1: an endothelial cell molecule important for the lipolytic processing of chylomicrons","volume":"18","author":"Young","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0435","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1194\/jlr.M800009-JLR200","article-title":"ApoE2-associated hypertriglyceridemia is ameliorated by increased levels of apoA-V but unaffected by apoC-III deficiency","volume":"49","author":"Gerritsen","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0440","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/nm.2297","article-title":"Brown adipose tissue activity controls triglyceride clearance","volume":"17","author":"Bartelt","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0445","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1161\/ATVBAHA.110.210815","article-title":"Intravenous injection of apolipoprotein A-V reconstituted high-density lipoprotein decreases hypertriglyceridemia in apoav\u2212\/\u2212 mice and requires glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1","volume":"30","author":"Shu","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0450","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1161\/01.ATV.0000130463.68272.1d","article-title":"Analysis of apolipoprotein A5, c3, and plasma triglyceride concentrations in genetically engineered mice","volume":"24","author":"Baroukh","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0455","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1194\/jlr.M600498-JLR200","article-title":"Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic mice","volume":"48","author":"Qu","year":"2007","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0460","doi-asserted-by":"crossref","first-page":"8342","DOI":"10.1073\/pnas.88.19.8342","article-title":"Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein","volume":"88","author":"Beisiegel","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0465","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1172\/JCI116081","article-title":"Lipoprotein lipase enhances binding of lipoproteins to heparan sulfate on cell surfaces and extracellular matrix","volume":"90","author":"Eisenberg","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0470","first-page":"3236","article-title":"Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice","volume":"119","author":"Stanford","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0475","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/hq0901.094500","article-title":"LR11, a mosaic LDL receptor family member, mediates the uptake of ApoE-rich lipoproteins in vitro","volume":"21","author":"Taira","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0480","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1161\/ATVBAHA.106.137091","article-title":"A secreted soluble form of LR11, specifically expressed in intimal smooth muscle cells, accelerates formation of lipid-laden macrophages","volume":"27","author":"Ohwaki","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0485","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1074\/jbc.272.6.3599","article-title":"Molecular identification of a novel candidate sorting receptor purified from human brain by receptor-associated protein affinity chromatography","volume":"272","author":"Petersen","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0490","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0140-6736(08)60208-1","article-title":"LDL-cholesterol concentrations: a genome-wide association study","volume":"371","author":"Sandhu","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2011.07.019_bib0495","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.atherosclerosis.2009.06.034","article-title":"Genetic variation at chromosome 1p13.3 affects sortilin mRNA expression, cellular LDL-uptake and serum LDL levels which translates to the risk of coronary artery disease","volume":"208","author":"Linsel-Nitschke","year":"2010","journal-title":"Atherosclerosis"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915011005983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915011005983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T09:13:40Z","timestamp":1560417220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915011005983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0021915011005983"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.07.019","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}